These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Systemic immunomodulatory therapy in severe dry eye secondary to inflammation. Cordero-Coma M; Anzaar F; Sobrin L; Foster CS Ocul Immunol Inflamm; 2007; 15(2):99-104. PubMed ID: 17558834 [TBL] [Abstract][Full Text] [Related]
6. [Dry eye syndrom--multispecialistic disease. Part two: diagnostic procedure and treatment]. Nowak M; Marek B; Kajdaniuk D; Siemińska L; Kos-Kudła B; Nowak K; Głogowska-Szelag J Wiad Lek; 2011; 64(1):49-55. PubMed ID: 21812364 [TBL] [Abstract][Full Text] [Related]
7. Management of dry eye disease. Lemp MA Am J Manag Care; 2008 Apr; 14(3 Suppl):S88-101. PubMed ID: 18452372 [TBL] [Abstract][Full Text] [Related]
8. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy. Toker E; Asfuroğlu E Cornea; 2010 Feb; 29(2):133-40. PubMed ID: 19966564 [TBL] [Abstract][Full Text] [Related]
9. [Anti-inflammatory treatment in dry eye disease]. Steven P; Cursiefen C Klin Monbl Augenheilkd; 2012 May; 229(5):500-5. PubMed ID: 22592340 [TBL] [Abstract][Full Text] [Related]
10. Occult thyroid eye disease in patients presenting with dry eye symptoms. Gupta A; Sadeghi PB; Akpek EK Am J Ophthalmol; 2009 May; 147(5):919-23. PubMed ID: 19211095 [TBL] [Abstract][Full Text] [Related]
11. Future directions in therapeutic interventions for conjunctival inflammatory disorders. Pflugfelder SC; Stern ME Curr Opin Allergy Clin Immunol; 2007 Oct; 7(5):450-3. PubMed ID: 17873588 [TBL] [Abstract][Full Text] [Related]
12. [A 0,05% cyclosporine treatment of the advanced dry eye syndrome]. Kujawa A; Rózycki R Klin Oczna; 2005; 107(4-6):280-6. PubMed ID: 16118939 [TBL] [Abstract][Full Text] [Related]
13. Essential fatty acids for dry eye: A review. Roncone M; Bartlett H; Eperjesi F Cont Lens Anterior Eye; 2010 Apr; 33(2):49-54; quiz 100. PubMed ID: 20031476 [TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapy of dry eye. Dogru M; Tsubota K Expert Opin Pharmacother; 2011 Feb; 12(3):325-34. PubMed ID: 21214414 [TBL] [Abstract][Full Text] [Related]
15. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Barber LD; Pflugfelder SC; Tauber J; Foulks GN Ophthalmology; 2005 Oct; 112(10):1790-4. PubMed ID: 16102833 [TBL] [Abstract][Full Text] [Related]
16. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Solomon A; Dursun D; Liu Z; Xie Y; Macri A; Pflugfelder SC Invest Ophthalmol Vis Sci; 2001 Sep; 42(10):2283-92. PubMed ID: 11527941 [TBL] [Abstract][Full Text] [Related]
17. The scientific context and basis of the pharmacologic management of dry eyes. Gilbard JP Ophthalmol Clin North Am; 2005 Dec; 18(4):475-84, v. PubMed ID: 16314213 [TBL] [Abstract][Full Text] [Related]
18. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Wilson SE; Perry HD Ophthalmology; 2007 Jan; 114(1):76-9. PubMed ID: 17070588 [TBL] [Abstract][Full Text] [Related]
19. Menopause and dry eye. A possible relationship. Versura P; Campos EC Gynecol Endocrinol; 2005 May; 20(5):289-98. PubMed ID: 16019376 [TBL] [Abstract][Full Text] [Related]
20. Dry eye syndrome and cataract as ocular manifestations of Crohn's disease. Mrugacz M; Sredzińska-Kita D; Cyrta-Jarocka E; Bakunowicz-Lazarczyk A Klin Oczna; 2005; 107(7-9):509-10. PubMed ID: 16417009 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]